Company Description
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States.
The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.
It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution.
In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product.
Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
| Country | United States |
| Founded | 1982 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 107 |
| CEO | Zachary B. Fleming |
Contact Details
Address: 1200 Summit Ave, Suite 414 Fort Worth, Texas 76102 United States | |
| Phone | 817-529-2300 |
| Website | sanaramedtech.com |
Stock Details
| Ticker Symbol | SMTI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000714256 |
| CUSIP Number | 79957L100 |
| ISIN Number | US79957L1008 |
| Employer ID | 59-2220004 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Ronald T. Nixon | Executive Chairman |
| Zachary B. Fleming | Chief Executive Officer |
| Michael D. McNeil | Chief Financial Officer and Corporate Secretary |
| Dr. Christopher A. Morrison FACHM, FAPWCA, FCCWS, M.D. | President of Telehealth Services |
| Callon Nichols | Vice President of Corporate Operations |
| Bill Fitzgerald | Chief Compliance Officer |
| Tricia Matteson | Vice President of Marketing |
| Tyler Palmer | Chief Corporate Development and Strategy Officer |
| Dr. Rebecca Erin Mcmahon | President of Research and Development |
| Seth Yon | President of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | 8-K | Current Report |
| Apr 15, 2024 | ARS | Filing |
| Apr 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 15, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 5, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 5, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 10-K | Annual Report |
| Mar 22, 2024 | 8-K | Current Report |
| Feb 22, 2024 | 8-K | Current Report |